Barts Cancer Institute
Queen Mary University of London

Dr Shah-Jalal Sarker

Research Interests

As a Lecturer in Biostatistics at the CECM, I lead the design and analysis of all cancer clinical trials and provide key input into all grant applications as well as being a trial statistician.

My collaborative research with other clinicians and scientists includes laboratory and epidemiological studies. My research interests include: cancer clinical trials; psychological effects of cancer; quality of life; measurement scales; cost-effectiveness trials; sample sizing; survival analysis; frailty modeling and missing data methods.
I provide Biostatistics consultancy to all BCI staff and students.

Teaching Interests

Biostatistics is key to research-led teaching. I am a mentor for the PGCAP programme and teaching lead for the Centre for Experimental Cancer Medicine. I teach Biostatistics & Research Methods modules as co-module lead (MSc courses: Cancer Therapeutics; Molecular Pathology & Genomics; Molecular & Cellular Biology; Clinical Oncology and Surgical Skills & Sciences).

My philosophy is to provide research-led, data-driven interactive teaching to non-specialist students via enhanced communication, feedback, and setting assessments for critical thinking. I was recently given a Teaching Award by the Queen Mary Student Union (QMSU).

Major Funders

- Cancer Research UK
- Department of Health

Contact Details

Email: s.sarker@qmul.ac.uk

Recent Publications

- Aspergillus lateral-flow device and qPCR testing in broncho-alveolar lavage fluid: A combination biomarker approach for the clinical diagnosis of invasive pulmonary aspergillosis. Johnson GL, **Sarker S-J**, et al. *The Journal of Clinical Microbiology* 2015.

- A phase Ib study investigating the combination of everolimus and dovinitib in vascular endothelial growth factor refractory clear cell renal cancer. Powles T, **Sarker S-J**, et al. *European Journal of Cancer* 2014, 50, 2057-2064.

- Repeatability of quantitative FDG-PET/CT and contrast enhanced CT in recurrent ovarian carcinoma: test retest measurements for tumor FDG uptake, diameter and volume. Rockall AG, Avril NE, ... **Sarker S-J**, McNeish IA and Brenton JD. *Clinical Cancer Research 2014.*

- Fertility and sexual function in long-term survivors of haematological malignancy. Using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. Greaves P, **Sarker S-J**, et al. *British Journal of Haematology* 2014, 164, 526–535.

- Psychosocial factors associated with impact of cancer in long term haematological cancer survivors. Korszun A, S**arker S-J** et al. *British Journal of Haematology* 2014, 164, 790–803

- A C++ program to calculate sample sizes for cost-effectiveness trials in a Bayesian framework. **Sarker S-J,** Whitehead, A and Khan I. *Computer Methods & Programs in Biomedicine* 2013; 110(3): 471-89.

- Smaller sample sizes for phase II trials based on exact tests with actual error rates by trading-off their nominal levels of significance and power. Khan I, **Sarker S-J** and Hackshaw A. *BJC* 2012, *107, 1801–*